Patents by Inventor Stefan Paskell

Stefan Paskell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090068139
    Abstract: There is disclosed a novel genus of small peptides, smaller than human TGF?, identified as having TGF? biological activity and therefore being useful as pharmacologic agents. It is further disclosed that both TGF? and the genus of small peptides disclosed herein have therapeutic activity to stimulate hematopoiesis, e.g., in patients undergoing cytotoxic cancer chemotherapy, and also act as cytoprotective agents to protect patients undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis, and otherwise to support the barrier function of the GI tract, such as when it is harmed by cytotoxic therapy.
    Type: Application
    Filed: October 31, 2007
    Publication date: March 12, 2009
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • Publication number: 20080242611
    Abstract: Disclosed are TGF-? polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Application
    Filed: February 11, 2008
    Publication date: October 2, 2008
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Patent number: 7365172
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF?, was discovered as having TGF? biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF? polypeptide. There is further disclosed that TGF? and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Grant
    Filed: July 16, 2004
    Date of Patent: April 29, 2008
    Assignee: Applied Protein Sciences LLC
    Inventors: Daniel R Twardzik, Stefan Paskell, Thomas S Felker
  • Patent number: 7329645
    Abstract: Disclosed are TGF-? polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Grant
    Filed: January 15, 2002
    Date of Patent: February 12, 2008
    Assignee: Applied Protein Sciences, LLC
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Publication number: 20060105957
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF?, was discovered as having TGF? biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF? polypeptide. There is further disclosed that TGF? and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Application
    Filed: July 16, 2004
    Publication date: May 18, 2006
    Applicant: Kaleidos Pharma, Inc.
    Inventors: Daniel Twardzik, Stefan Paskell, Thomas Felker
  • Patent number: 6815418
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: November 9, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Patent number: 6764683
    Abstract: There is disclosed a novel genus of small peptides, much smaller than human TGF&agr;, was discovered as having TGF&agr; biological activity and therefore are useful as pharmacologic agents for the same indications as full length TGF&agr; polypeptide. There is further disclosed that TGF&agr; and consequently the genus of small peptides disclosed herein, was found to have therapeutic activity to stimulate hematopoiesis in patients undergoing cytotoxic cancer chemotherapy and to act as a cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal (GI) side effects, such as mucositis and otherwise support the barrier function of the GI tract when it is harmed by cytotoxic therapy.
    Type: Grant
    Filed: December 13, 1999
    Date of Patent: July 20, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • Patent number: 6677307
    Abstract: Disclosed are TGF-60 mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.
    Type: Grant
    Filed: May 1, 2002
    Date of Patent: January 13, 2004
    Assignee: Kaleidos Pharma, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell, John M. Reno
  • Publication number: 20030036509
    Abstract: Disclosed are TGF-60 mimetics that PEGylated TGF-&agr; polypeptides and PEGylated TGF-60 related polypetides or fragments thereof.
    Type: Application
    Filed: May 1, 2002
    Publication date: February 20, 2003
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell, John M. Reno
  • Publication number: 20020193301
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Application
    Filed: January 4, 2002
    Publication date: December 19, 2002
    Applicant: Stem Cell Pharmaceuticals, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Patent number: 6486122
    Abstract: Disclosed are peptides related to human TGF-&agr;, having TGF-&agr; biological activity, which are useful for many of the indications that full-length TGF-&agr; polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-&agr; and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-&agr; related peptides to related neurodengenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.
    Type: Grant
    Filed: April 26, 2000
    Date of Patent: November 26, 2002
    Assignee: Stem Cell Pharmaceuticals, Inc.
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • Publication number: 20020169119
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Application
    Filed: August 17, 2001
    Publication date: November 14, 2002
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell
  • Publication number: 20020169131
    Abstract: Disclosed are peptides related to human TGF-&agr;, having TGF-&agr; biological activity, which are useful for many of the indications that full-length TGF-&agr; polypeptide is useful. Also provided are methods of use of such peptides, as well as human TGF-&agr; and biologically related polypeptides. For example, methods for treating or preventing cachexia in subjects are provided as well as methods for stimulating hematopoiesis in patients undergoing cytotoxic chemotherapy. In addition, the use of TGF-&agr; related peptides to related neurodengenerative diseases is also provided. Methods of the invention also provide protection for patients undergoing cytotoxic therapy from side effects such as gastrointestinal (GI) mucositis.
    Type: Application
    Filed: September 12, 2001
    Publication date: November 14, 2002
    Inventors: Daniel R. Twardzik, Stefan Paskell, Thomas S. Felker
  • Publication number: 20020123465
    Abstract: Disclosed are TGF-&agr; polypeptides, related polypeptides, fragments and mimetics thereof useful in stimulating stem cell or precursor cell proliferation, migration and differentiation. The methods of the invention are useful to treat tissue injury as well as expand stem cell populations in, or obtained from, gastrointestinal, musculoskeletal, urogenital, neurological and cardiovascular tissues. The methods include ex vivo and in vivo applications.
    Type: Application
    Filed: January 15, 2002
    Publication date: September 5, 2002
    Applicant: Stem Cell Pharmaceuticals, Inc.
    Inventors: Daniel R. Twardzik, Andre Pernet, Thomas S. Felker, Stefan Paskell